Wockhardt Ltd (WOCKPHARMA) – Strategy, SWOT and Corporate Finance Report

Wockhardt Ltd (WOCKPHARMA) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). It operates in India, the US, the UK and the emerging markets. Wockhardt is headquartered in Mumbai, Maharashtra, India.

Scope

• Detailed information on Wockhardt Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Wockhardt Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Wockhardt Ltd including a breakdown and examination of key business segments

• News about Wockhardt Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Wockhardt Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Wockhardt Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Wockhardt Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Dr. Reddy's Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Sandoz Inc

Alcon Inc

Cipla Ltd

ANI Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Wockhardt Ltd - Key Facts

Wockhardt Ltd - Key Employees

Wockhardt Ltd - Key Employee Biographies

Wockhardt Ltd - Major Products and Services

Wockhardt Ltd - History

Wockhardt Ltd - Company Statement

Wockhardt Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Wockhardt Ltd - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: India

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United States

Performance

R&D Overview

Wockhardt Ltd - Corporate Strategy

Wockhardt Ltd - SWOT Analysis

SWOT Analysis - Overview

Wockhardt Ltd - Strengths

Wockhardt Ltd - Weaknesses

Wockhardt Ltd - Opportunities

Wockhardt Ltd - Threats

Wockhardt Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Wockhardt Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Nov 14, 2023: Wockhardt Reports an Excellent Quarter Q2 Revenue Jumps by 11%

Aug 14, 2023: Wockhardt’s Q1 FY24 3 Fold Growth in EBITDA Over Q1 FY23

Aug 14, 2023: Wockhardt : Financial Results

Jul 18, 2023: Wockhardt : Appointment of Ms. Amelia Fernandes as Additional (Independent) Director of the Company

May 26, 2023: Wockhardt’s Q4 FY23 3 Fold Jump in EBITDA over Q4 FY22

Feb 13, 2023: Wockhardt’s Q3 FY23 EBITDA Growth 37% Over Q2 FY23

Nov 04, 2022: Wockhardt’s Q2 FY23 Topline growth 14% and EBITDA growth 369% over previous quarter

Aug 20, 2022: Wockhardt : Re-structuring of US business

Aug 12, 2022: Wockhardt’s Q1 FY23 EBITDA at Rs.(16 cr) EBITDA before R&D at Rs.20 cr

May 30, 2022: Wockhardt’s FY22 Revenue grew by 17% over FY21. Long Term Debt reduced by Rs 450 Cr. Successful Rights Issue of Rs.748 Cr.

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Wockhardt Ltd, Key Facts

Wockhardt Ltd, Key Employees

Wockhardt Ltd, Key Employee Biographies

Wockhardt Ltd, Major Products and Services

Wockhardt Ltd, History

Wockhardt Ltd, Other Locations

Wockhardt Ltd, Subsidiaries

Wockhardt Ltd, Key Competitors

Wockhardt Ltd, Ratios based on current share price

Wockhardt Ltd, Annual Ratios

Wockhardt Ltd, Annual Ratios (Cont…1)

Wockhardt Ltd, Annual Ratios (Cont…2)

Wockhardt Ltd, Interim Ratios

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Wockhardt Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Wockhardt Ltd, Performance Chart (2019 – 2023)

Wockhardt Ltd, Ratio Charts

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports